U.S. Markets closed

U.S. Stem Cell, Inc. (USRM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0231+0.0002 (+0.87%)
At close: 3:54PM EDT

U.S. Stem Cell, Inc.

1560 Sawgrass Corporate Parkway
4th Floor
Sunrise, FL 33323
United States
954-835-1500
http://www.us-stemcell.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael TomasCEO, Pres, CFO & Director1.81MN/A1966
Dr. Colleen RobbSr. Compliance OfficerN/AN/AN/A
Mr. Phil PosaSr. VP of U.S. & International SalesN/AN/AN/A
Ms. Evelyn FloresCorp. ControllerN/AN/AN/A
Dr. Sergio PinskiMedical Director & Member of Scientific Advisory BoardN/AN/AN/A
Mr. James L. GreeneClinical Operations ConsultantN/AN/AN/A
Fabianne GershonConsultantN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is based in Sunrise, Florida.

Corporate Governance

U.S. Stem Cell, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.